Alnylam's Amvuttra Seen as Mega Blockbuster -- Market Talk

Dow Jones

2025/03/21

0739 ET - The FDA's approval of Alnylam's Amvuttra in the cardiomyopathy of transthyretin-mediated amyloidosis, or ATTR-CM, puts the drug well on track to achieving mega blockbuster status, Citi says. Analysts David Lebowitz and Ike Lee say the drug's label was clean and overall in line with their expectations, which they say will enable strong uptake. The green light makes Amvuttra the only U.S. drug approved to address both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis, a factor Citi says could resonate with practitioners. Alnylam up 4.5% premarket to $265. (colin.kellaher@wsj.com)

(END) Dow Jones Newswires

March 21, 2025 07:39 ET (11:39 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2521384400"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2521384400\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2521384400?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-21 19:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521384400","market":"sh","top_or_hot":-1,"title":"Alnylam's Amvuttra Seen as Mega Blockbuster -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0739 ET - The FDA's approval of Alnylam's Amvuttra in the cardiomyopathy of transthyretin-mediated amyloidosis, or ATTR-CM, puts the drug well on track to achieving mega blockbuster status, Citi says. Analysts David Lebowitz and Ike Lee say the drug's label was clean and overall in line with their expectations, which they say will enable strong uptake. The green light makes Amvuttra the only U.S. drug approved to address both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis, a factor Citi says could resonate with practitioners. Alnylam up 4.5% premarket to $265. (colin.kellaher@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 21, 2025 07:39 ET (11:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alnylam's Amvuttra Seen as Mega Blockbuster -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlnylam's Amvuttra Seen as Mega Blockbuster -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-21 19:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0739 ET - The FDA's approval of Alnylam's Amvuttra in the cardiomyopathy of transthyretin-mediated amyloidosis, or ATTR-CM, puts the drug well on track to achieving mega blockbuster status, Citi says. Analysts David Lebowitz and Ike Lee say the drug's label was clean and overall in line with their expectations, which they say will enable strong uptake. The green light makes Amvuttra the only U.S. drug approved to address both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis, a factor Citi says could resonate with practitioners. Alnylam up 4.5% premarket to $265. (colin.kellaher@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 21, 2025 07:39 ET (11:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2521384400","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521384400","pubTimestamp":1742557140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0739 ET - The FDA's approval of Alnylam's Amvuttra in the cardiomyopathy of transthyretin-mediated amyloidosis, or ATTR-CM, puts the drug well on track to achieving mega blockbuster status, Citi says. Analysts David Lebowitz and Ike Lee say the drug's label was clean and overall in line with their expectations, which they say will enable strong uptake. The green light makes Amvuttra the only U.S. drug approved to address both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis, a factor Citi says could resonate with practitioners. Alnylam up 4.5% premarket to $265. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4139":"生物科技","ALNY":"阿尔尼拉姆制药公司"},"translate_title":"Alnylam的Amvuttra被视为重磅炸弹——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":0.9},"content_text":"0739 ET - The FDA's approval of Alnylam's Amvuttra in the cardiomyopathy of transthyretin-mediated amyloidosis, or ATTR-CM, puts the drug well on track to achieving mega blockbuster status, Citi says. Analysts David Lebowitz and Ike Lee say the drug's label was clean and overall in line with their expectations, which they say will enable strong uptake. The green light makes Amvuttra the only U.S. drug approved to address both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis, a factor Citi says could resonate with practitioners. Alnylam up 4.5% premarket to $265. (colin.kellaher@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 07:39 ET (11:39 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}